Genmab A/S (NASDAQ:GMAB) Hits New 12-Month High – Here’s What Happened

Genmab A/S Sponsored ADR (NASDAQ:GMAB) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $34.97 and last traded at $34.9120, with a volume of 594683 shares traded. The stock had previously closed at $33.87.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GMAB. Truist Financial reaffirmed a “buy” rating and issued a $48.00 price objective (down from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target on the stock in a report on Tuesday, September 23rd. Zacks Research lowered shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Finally, HC Wainwright raised their target price on shares of Genmab A/S from $40.00 to $41.00 and gave the stock a “buy” rating in a report on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and an average price target of $39.75.

Genmab A/S Stock Down 4.7%

The stock’s 50 day moving average price is $31.83 and its 200-day moving average price is $28.13. The stock has a market capitalization of $20.72 billion, a PE ratio of 13.72, a price-to-earnings-growth ratio of 2.34 and a beta of 0.90.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.17. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $975.40 million. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. As a group, sell-side analysts predict that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in shares of Genmab A/S by 17.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock worth $19,282,000 after acquiring an additional 135,814 shares in the last quarter. Squarepoint Ops LLC grew its holdings in Genmab A/S by 636.3% in the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock worth $1,947,000 after purchasing an additional 81,434 shares during the last quarter. Eagle Global Advisors LLC grew its holdings in Genmab A/S by 16.3% in the third quarter. Eagle Global Advisors LLC now owns 244,470 shares of the company’s stock worth $7,498,000 after purchasing an additional 34,175 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Genmab A/S during the second quarter worth $257,000. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Genmab A/S by 152.3% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock valued at $71,367,000 after purchasing an additional 2,084,966 shares during the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.